Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Goldin

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Journal of Medical Imaging (Bellingham, Wash.)|April 28, 2023
Integration and evaluation of chest X-ray artificial intelligence in clinical practiceKoon-Pong Wong, Suzanne Y Homer, Sindy H Wei, et al.
Radiology|June 30, 2009
Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatmentWhitney B Pope, Hyun J Kim, Jing Huo, et al.
American Journal of Respiratory and Critical Care Medicine|August 16, 2005
Computed tomography in the evaluation of cystic fibrosis lung diseaseAlan S Brody, Harm A W M Tiddens, Robert G Castile, et al.
Plos One|November 10, 2017
Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung diseaseViktor Martyanov, Grace-Hyun J Kim, Wendy Hayes, et al.
Neuro-Oncology|November 9, 2021
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenibBenjamin M Ellingson, Grace Hyun J Kim, Matt Brown, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|May 12, 2017
Obstructive pulmonary disease in patients with previous tuberculosis: Pathophysiology of a community-based cohortBrian W Allwood, Rencia Gillespie, Maya Galperin-Aizenberg, et al.
Arthritis Care & Research|August 4, 2025
International Investigation of the Gut-Lung Axis in Systemic Sclerosis-Interstitial Lung DiseaseKristofer Andréasson, Arissa Young, Swapna Joshi, et al.
The Lancet. Respiratory Medicine|September 1, 2020
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trialDinesh Khanna, Celia J F Lin, Daniel E Furst, et al.
The Lancet. Respiratory Medicine|October 3, 2019
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trialLuca Richeldi, Evans R Fernández Pérez, Ulrich Costabel, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 25, 2019
Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18Elizabeth R Volkmann, Donald P Tashkin, Masataka Kuwana, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Journal of Medical Imaging (Bellingham, Wash.)|April 28, 2023
Integration and evaluation of chest X-ray artificial intelligence in clinical practiceKoon-Pong Wong, Suzanne Y Homer, Sindy H Wei, et al.
Radiology|June 30, 2009
Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatmentWhitney B Pope, Hyun J Kim, Jing Huo, et al.
American Journal of Respiratory and Critical Care Medicine|August 16, 2005
Computed tomography in the evaluation of cystic fibrosis lung diseaseAlan S Brody, Harm A W M Tiddens, Robert G Castile, et al.
Plos One|November 10, 2017
Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung diseaseViktor Martyanov, Grace-Hyun J Kim, Wendy Hayes, et al.
Neuro-Oncology|November 9, 2021
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenibBenjamin M Ellingson, Grace Hyun J Kim, Matt Brown, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|May 12, 2017
Obstructive pulmonary disease in patients with previous tuberculosis: Pathophysiology of a community-based cohortBrian W Allwood, Rencia Gillespie, Maya Galperin-Aizenberg, et al.
Arthritis Care & Research|August 4, 2025
International Investigation of the Gut-Lung Axis in Systemic Sclerosis-Interstitial Lung DiseaseKristofer Andréasson, Arissa Young, Swapna Joshi, et al.
The Lancet. Respiratory Medicine|September 1, 2020
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trialDinesh Khanna, Celia J F Lin, Daniel E Furst, et al.
The Lancet. Respiratory Medicine|October 3, 2019
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trialLuca Richeldi, Evans R Fernández Pérez, Ulrich Costabel, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 25, 2019
Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18Elizabeth R Volkmann, Donald P Tashkin, Masataka Kuwana, et al.
Pageof 11